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Section I: Title and Abstract 
Abstract 
Problem: According to The International Agency for Research on Cancer (IARC) 2020 World 
Cancer Report, cancer has contributed to 9.6 million deaths in 2018 and is now globally 
considered the second most common cause of death (IARC, 2020).  
Context: As a cancer patient moves beyond diagnosis, there becomes a need to introduce the 
plan of care and education related to evidence-based treatments with an intent to cure. As the 
delivery of these treatments continues to move toward outpatient care, herein lies the challenge 
of sharing important information with the patient to improve health outcomes.  
Intervention: This DNP change of practice project used an evidence-based educational training 
toolkit and educational endeavor targeting oncology nurse coordinators.  
Measures: The author developed Nurse-Led Pre-Treatment Education Experience Survey that 
was used to collect baseline data pre-and post-training to measure project outcomes.  
Results: Thirteen Nurse Coordinators participated in this educational change of practice. It was 
anticipated that through education and a toolkit, nurse knowledge would increase by 20 %. The 
data analyzed after the intervention showed an increase in nurse knowledge of 35%.  
Conclusion: The value of providing an educational toolkit for use by oncology nurses  
has shown to improve knowledge and comfort levels for these providers and enable the patient to 
self-manage potential treatment-related side effects.  
Keywords: nurse, nurse coordinator, patient education, navigator, chemotherapy teaching    
  
8 
The Nurse Will See You Now: Improving Nurse-Led Chemotherapy Teaching 
Section II: Introduction 
Background 
Breast cancer has become the most prevalent cancer besides skin cancer to affect women 
in the United States (American Society of Clinical Oncology [ASCO], 2019).  According to the 
National Cancer Institute Surveillance, Epidemiology, and End Results Program (SEER), it is 
estimated that 268,600 (15.2%) new cases of female invasive breast cancer are expected to be 
diagnosed in 2019, affecting about one in eight (12%) of women over their lifetime. Of those 
diagnosed, it is estimated that 40,920 (6.7%) are expected to die (National Cancer Institute 
[NIH], 2018).  Fortunately, due to recent advances in life-saving treatments for breast cancer, 
there are multiple options to offer the patient: surgery, radiation, chemotherapy, targeted 
therapies, hormonal therapies, and clinical trials (Breastcancer.org, 2019).  
Problem Description 
Oncology care in an academic medical oncology outpatient setting is complex, requiring 
multidisciplinary team-based models to give the most effective, safe, and efficient patient 
care. The role of the oncology nurse coordinator (NC) or multidisciplinary care coordinator 
(MCC) was developed to respond to this complex system. Navigation of the system has become 
a standard of care by which cancer programs become accredited by the Commission on Cancer 
(Swanson, Strusowski, Mack, & Degroot, 2012).   
The oncology nurse coordinator role in a large academic outpatient oncology clinic is 
continually being modified to better assist the patient care team in improving patient education. 
After the plan of care is put together by the medical oncologist, along with input from the 
patient, it becomes necessary to educate the patient on what to expect and how to manage this 
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phase of treatment. This experience consists of pre-treatment care planning and conducting a 
clinic visit to inform the chemotherapy-naive patient before treatment to potentially improve the 
patient's overall treatment journey.   
Setting 
According to Oncology.stanford.edu. (2019) the specialized care offered in these 
oncology clinics includes advanced treatment and supportive, compassionate care to treat every 
stage of breast and gynecologic cancer, including genetic counseling, participation in clinical 
trials, and survivorship support. The website states that they are family-centered and merge 
advanced technology and team-based supportive care to assist patients with their treatment plans 
(Oncology.stanford.edu, 2019).  This team-based care includes an oncology nurse experienced in 
treating cancer patients and is vital to the multidisciplinary care coordination program.  Members 
of this team include the Medical Doctor (MD), Advance Practice Provider (APP), Oncology 
Nurse Coordinator (NC), Clinical Administrator (CAA), and Medical Assistant (MA). They all 
play an essential role in helping personalize the treatment plan.  
Nurse coordinators in this DNP student's clinic are not fully utilized as supportive clinical 
professionals to help offload the educational burden from the APP to optimize team-based care. 
A current high-level initiative in the Women's Cancer Center clinics to help transition the nurse 
coordinator to be more patient-facing and involved with patient education is underway. This 
project supports this focus to succeed by utilizing the NC to offload this educational visit from 
the APP allowing the APP to increase their patient volume in independent clinics with a resulting 







This project's global aim was to improve chemotherapy teaching for newly diagnosed 
cancer patients by implementing standardized education and documentation to enable the nurse 
in the outpatient clinical setting to teach the patient population competently. This DNP quality 
improvement project introduced a clinic-specific toolkit in educational training for the nurses to 
allow patients and caregivers to know what to expect during their chemotherapy routine and 
improve the patient experience at the first treatment visit.   
 Improvements in this DNP student's local setting have allowed for expanded use in other 
cancer outpatient clinics to help encourage the NC to independently teach the pre-treatment 
education as the toolkit is easily modified for a specific cancer population.  The project was 
implemented in December 2019.  Measurable project outcomes included: 
RN knowledge base related to imperative information necessary to educate the patient 
before the first treatment will increase by 20%. 
RN knowledge base related to the nurse's role in conducting a pre-treatment educational 
visit will increase by 20%. 
RN knowledge base related to how the pre-treatment educational visit will be scheduled 
will increase by 20%. 
RN knowledge related to how to document the pre-treatment educational visit will 










 This review investigated and identified the current practice of oncology patient pre-
treatment education and strategies utilized to improve communication of this critical phase of the 
patient's care. The following PICO(T) question was developed to direct the search for nurse-led 
education's effectiveness and use of an evidence-based toolkit that would benefit patient care in 
the oncology clinics at Stanford Healthcare: In the breast and gynecology oncology clinics, does 
the use of a standardized chemotherapy teaching toolkit, as compared to no standardized process, 
increase the nurse's effectiveness/confidence to conduct the patient's pre-treatment educational 
clinic visit? 
Search Methodology 
I conducted a comprehensive literature review, utilizing the most up-to-date evidence-
based information to justify and gather tools for this project.  Topic-specific keywords were 
used, such as a nurse, nurse coordinator, patient education, navigator, and chemotherapy 
teaching.  Databases searched included the Cumulative Index to Nursing and Allied Health Line 
(CINAHL), PubMed, Oncology Nursing Society (ONS), Google Scholar, and Academy of 
Oncology Nurse Navigators utilizing English-language material published between 2008 to 2020 
Many systemic reviews and articles discussed how the nurse as a patient educator helped 
increase patient satisfaction.  
The extensive literature review identified approximately 20 articles with the potential to 
be utilized for this process. Papers selected for inclusion were those most relevant to this author's 
intervention and specific to the PICOT question.  The Johns Hopkins Nursing Evidence 
Appraisal tools were used (Dang & Dearholt, 2018) to identify the exact steps necessary to 
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evaluate the evidence to determine the practice question and develop recommendations related to 
practice change. A summary of the final eight articles deemed most relevant is presented below. 
      Review of the Literature 
Jivraj et al. (2018) discussed how a nurse-led chemotherapy educational class increased 
patient knowledge to decrease anxiety and made sure the patients had the necessary information 
pre-treatment to reduce post-treatment confusion related to side effects. The authors reviewed 
data at a large oncology cancer center over one month. Nurses collected metrics relating to 37 
patients who started a new treatment.  Post-treatment phone call logs showed that out of the 168 
calls, 139 were related to symptom management, with six having to do with medication 
questions and 23 about scheduling. With approximately 83% of needs related to symptoms, it 
was determined that it would behoove the center to develop a tailored pre-treatment educational 
class. The evidence-based material was gathered, and a course was designed to teach the 
necessary information with a notable decrease in post-treatment patient-related questions.  
Unfortunately, metrics were not collected, but according to the authors, the post 
educational patient evaluations showed that individualized pre-treatment education was more 
valuable concerning a broad group class than one that was not tailored to specific chemotherapy 
agents. This project could help support a pre-treatment educational visit to help the patient gain 
the necessary knowledge of treating post-treatment potential side-effects without sending a 
message or calling the team with every concern. It also showed the value of giving this visit in an 
individual format versus a generic class.  
Mann (2011) conducted a quality improvement project, highlighting the benefits of 
having the oncology nurse deliver the individualized pre-treatment patient teaching in a 
controlled learning environment. This educational intervention aimed to improve the current 
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system of providing education to newly diagnosed patients with cancer by assessing individual 
patient needs and providing education before treatment.  Methods included identifying two 
groups of patients, Group A, those newly diagnosed and given the intervention (teaching by the 
nurse), and Group B, former treatment patients who did not receive this teaching.  Both groups 
were then asked how the educational information from the nurse could be improved. The study 
found that group A participants were overwhelmingly satisfied with the teaching. 
In contrast, group B had numerous suggestions on improving the pre-treatment education 
to navigate post-treatment sequelae. This study was helpful as it showed the importance of 
utilizing an assessment tool to evaluate patient literacy level, reading skills, cultural or religious 
aspects, available support systems, and anxiety levels before giving patients information about 
their upcoming treatment. The data amassed in this study also shows that it would be beneficial 
to conduct the NC educational visit before the first treatment and to individualize the education 
to address specific needs and preferences.  
An existing pre-treatment patient educational study was evaluated at a large academic 
outpatient oncology facility. The author intended to see if eighty-one cancer patients and 
caregivers who were shown a video followed by a nurse-facilitated group educational class 
found this information helpful in managing post-treatment side effects. According to Fee-
Schroeder et al. (2013), this coordinated curriculum had previously not existed. Of those 
participants who did not already begin chemotherapy, (n=42) was given an initial survey which 
showed that 98 % of patients and caregivers felt the intervention increased their understanding of 
side effects and how to manage them. Results also showed that 98 % felt this education increased 
motivation to utilize self-management strategies such as increasing physical activity and fluid 
intake, as well as modifying dietary behaviors. Other themes identified that the participants 
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planned to modify their behavior and communicate more frequently with the medical team 
regarding ways to cope. The survey was again completed at eight weeks, and 24 participants 
(69%) reported they continued to use these strategies learned in the class. 
The authors stressed the limitations included using a convenience sample in that the 
chemotherapy class was optional, and those who did attend were potentially more motivated to 
learn. The authors also did not assess the nurse discussion and video value separately, so benefits 
could not be attributed to either intervention. Lastly, although the questionnaire was based on 
prior patient surveys, it was not validated. 
A randomized, controlled study by Aranda et al. (2011) was conducted to assess how pre-
treatment chemotherapy education would affect patient distress, treatment-related concerns, and 
the severity of post-treatment side effects of patients commencing chemotherapy. One hundred 
and ninety-two cancer patients were recruited to receive various educational interventions before 
the first treatment (intervention 1), a follow-up telephone call 48 hours after the first treatment 
(intervention 2), and a final in-person review immediately before the second treatment 
(intervention 3). After measuring patient outcomes from baseline (T1) and before proceeding 
with cycle 1 of treatment (T2) and cycle 2 (T3), it was found that patient distress was not 
significantly reduced. However, they did find that these pre-treatment interventions did show a 
significant decrease in psychological (P=0.027), procedural concerns (P=0.03), and a reduction 
of symptoms of vomiting (P=0.001) by T3. Its findings suggest promise in that pre-treatment 
chemotherapy education shows some improvement in patient treatment-related concerns along 
with physical/psychological outcomes. They also recommend further research with more robust 
patient populations to generalize the findings across varied settings.  
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Dalby et al. (2013) discussed a process improvement project conducted by a team of 
oncology nurses that utilized three interventions as "a checklist, a treatment-specific calendar, 
and a patient education assessment survey" (p. 473). Patient satisfaction related to this education 
was evaluated one month after implementation by distributing a five-point Likert-type scale 
questionnaire to patients at their third treatment visit. This information helped guide follow-up 
information specific to educational and written material to give to the patient. Outcomes reported 
53 patients scored an average satisfaction score of 4.86 (on a scale of 0-5) regarding how patients 
manage side effects after the intervention (Dalby et al., 2013). The most significant increase was 
found regarding patients reporting what to expect during their treatment from a baseline score of 
91% and how to manage side effects score of 87% with a post-intervention satisfaction score of 
97% in both knowledge and ability to manage chemotherapy-related side effects.  This study is 
essential as it showed that utilizing materials such as checklists, calendars, and patient surveys, 
which are readily available, may help increase patient satisfaction related to patient education. A 
pre-treatment toolkit, which this DNP student compiled, would contain all relevant evidence-
based material in an easy to utilize format.  
Wagner et al. (2018) discussed whether newly diagnosed cancer patients have an 
improvement in the quality of life and overall patient experience with the intervention of a nurse 
navigator involved in their supportive care.  Two hundred and fifty-one adult patients recently 
diagnosed with breast, colorectal, or lung cancer were randomized to receive usual enhanced 
care (n-=118) or nurse navigator support (n=133) for four months. The primary care physicians 
were utilized as units of randomization in a two-group cluster-randomized, controlled trial. Self-
reported measures from The Functional Assessment of Cancer Therapy-General (FACT-G), 
Quality of Life scale, three subscales of the Patient Assessment of Chronic Illness Care (PACIC) 
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were collected at baseline, four months, and 12 months via a self-reported experience survey. 
According to the authors, baseline mean scores for the population were higher than for random 
samples of adults with cancer (83 v 80). This finding, according to the authors, may be that the 
cohort only consisted of patients who were receiving treatment with an intent to cure and not 
palliative, and high socioeconomic status of the enrollees.  The patients who received the nurse 
navigator intervention had significantly higher scores on the PACIC summary scores as noted by 
higher mean scores received at four and again at 12 months.  Study limitations did include a 
limited sample size.  The authors concluded that nurse navigator support for patients with an 
early diagnosis of cancer improves the patient experience and reduces care problems compared 
with usual enhanced care. Still, the quality of life was not differentially affected.  
A study conducted by Munoz, Farshidpour, Chaudhary, and Fathi (2018), found that 
newly diagnosed cancer patients face challenges related to delays in care, lack of information, 
and inadequate attention to emotional and social problems. Incorporating a cancer nurse 
navigator helps to improve coordination and communication to increase patient satisfaction and 
care. The purpose, as described by the authors, was to evaluate a multidisciplinary cancer care 
model at two endpoints: (a) time from diagnosis to initiation of treatment and (b) an average 
number of missed appointments.   
This retrospective cohort study was completed to determine if an Oncology Nurse 
Navigator (ONN) effectively improved these two variables. The experimental group included 
patients assigned to an ONN, 34 men and 26 women. The control group was not given an ONN 
and consisted of 35 men and 25 women. Findings suggest that an ONN's inclusion as part of the 
multidisciplinary cancer care model experienced a significantly shorter time between diagnosis 
to treatment (p < 0.001) than those not assigned an ONN. They also found no statistical 
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difference in missed appointments between the two groups (p = 0.7). Findings further established 
that the ONN's inclusion helped facilitate the number of patients referred to the multidisciplinary 
tumor board review. Patients referred to the tumor board have shown to have better outcomes.  
Lastly, the authors discussed a potential bias within the study because it was conducted within a 
multidisciplinary cancer care model, and that reality may have affected outcomes as 
multidisciplinary care centers tend to have higher levels of care in general.  
Apor et al. (2017) gave oncology patients a pre-evaluation survey to assess their 
perceived understanding of various treatment topics after discussing the proposed treatment with 
their medical oncologist. The patients then received teaching by an oncology nurse, and the 
survey was re-administered when they returned for their first and second treatment cycles. The 
goal was to evaluate the effect of a nurse-led chemotherapy teaching session on the patient's 
knowledge, anxiety, and feeling of being prepared for the treatments. As noted by the authors, 
one hundred and ninety-six patients enrolled in the study and completed a survey before their 
teaching. One hundred eighty-two patients completed the survey again before cycle one. Finally, 
a third survey was conducted by one hundred and seventy-one patients.  Responses noted at the 
second cycle of chemotherapy showed no statistically significant decrease in how patients felt 
contacting a physician caused them to feel anxious (p=0.0801) or how treatment-related side 
effects caused anxiety (p=0.2737). Statistically significant increases were observed in three 
patient indicators such as patients' perceived knowledge of the treatment schedule, potential side 
effects, and medications to help prevent treatment-related side effects ( p= <0.001). Study 
limitations, as noted by the authors, were that the survey instrument was not previously 
validated. A group of clinical oncologists reviewed the tool for construct and content validity 
before initiation to address this lack of validity.  Also, the authors did not collect information 
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related to the patient's disease stage. This information may have affected the results as some 
stages are not curable, and only palliative options were available to the patient. 
Summary of the Evidence 
 Much heterogeneity exists in the literature and suggests that a well-structured 
educational intervention related to the NC teaching pre-treatment information to chemotherapy 
naïve patients helps increase patient knowledge and decrease anxiety. This education has the 
added benefit of enabling the patient to self-manage common treatment-related side effects. 
However, few articles discussed how a nurse navigator educating patients was a cost-effective 
method and how nurses felt their educator's role helped the navigation process. A summary of 
the most relevant evidence is presented in an evaluation table (Appendix C for Literature Review 
Evaluation Table).  
Rationale 
 A well-developed planning model such as Precede-Proceed enabled the process to be 
more effective and efficient. This model was first proposed in 1974 by Lawrence W. Green, a 
public health education specialist, as an evaluation framework. It became known as Precede in 
1980 and later expanded upon by Green and Kreuter in 1991 to include Proceed (Porter, 2016). 
This model, as explained by Connon and Salazar (2004), utilizes the stages of assessment 
(Precede) and intervention (Proceed) by breaking it down to understand further the key elements 
such as policies, regulations, and resources in play that will either benefit or hinder the measure. 
The authors also identify the five types of assessment required to adequately "diagnose" the 
population's unique needs before proceeding, such as social, epidemiologic, 
behavioral/environmental, educational/organizational, and administrative/policy. Concerning 
social diagnosis, assessing the population's perception of its own needs is necessary. The 
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population related to this DNP project are the stakeholders involved in making this plan a 
success along with the oncology patients it will affect. As previously discussed, the staff 
educated on the toolkit are the NCs in the oncology clinics, which utilized the information to 
teach newly diagnosed cancer patients the most relevant, evidence-based information before they 
commenced their first treatment.  
The determination of which health problems are of the most significant concern to the 
population were epidemiologic. This included breast and gynecological newly diagnosed patients 
with cancer who will receive treatments to help "cure" or potentially decrease the risk of cancer 
recurring and/or becoming "incurable." Behavioral/environmental, as determined by the authors, 
would identify which problems would have the most significant importance to the population. 
For this change of process project, it is helpful to identify stakeholders’ attitudes, knowledge, 
and beliefs related to reinforcing reward and enabling factors that would support cultural change. 
According to Melnyk and Fineout-Overholt (2011), a culture of "best practice" would need to be 
established to consistently implement EBP in healthcare organizations.  Regardless of their 
educational status, all nursing staff should be educated and encouraged to utilize evidence-based 
practice. The authors suggest that it is also helpful to have EBP mentors to help implement and 
sustain an EBP culture.  
As a DNP student in an academic healthcare system, I conducted a presentation early in 
the process regarding a process improvement plan to clinic stakeholders to introduce and define 
the project. It was necessary to include information related to how utilizing EBP when 
undertaking a program such as this was important to ensure patients receive the most relevant 
information. Learning how to conduct an improvement plan and how to use evidence-based 
processes will help the staff feel they have a stake in the outcome and success.  
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Educational/organizational diagnosis relates to establishing how the stakeholders feel 
their education and skills will enable them to adequately teach the patient population. It also may 
refer to how they feel the organization has equipped them with the most useful tools to utilize in 
teaching the patient. The change of process plan educated the stakeholders and encouraged the 
use of a standardized, evidence-based toolkit.  
Lastly, identifying policies, regulations, and resources that would either hinder or 
enhance implementation is referred to as administrative policy (Connon & Salazar, 2004). This is 
best accomplished by involving leadership, clinical educators, and internet technologists (IT) to 
distinguish what information is appropriate to utilize with Stanford Healthcare branding and how 
to potentially bill for the NC pre-teaching visit. For this process improvement plan, this author 
used leadership to advise regarding the overall scope and potential resources that could be tapped 
into to support the project. The oncology nurse educator was then introduced to this project with 
an aim to increase the project's breadth and communicate the author’s intention along with 
reaching out to other oncology clinics at Stanford Healthcare. IT educators were then involved in 
designing an electronic version of the toolkit to share this information more easily via electronic 
means, help with literacy review and language development.  
After assessing the population, the authors suggest moving on to the proceed measure of 
the model. This includes planning, implementation, and evaluation. It is known that making 
decisions about behaviors is sometimes complicated. The model considers this complexity and 
helps set priorities and determination making in a systematic approach to include 
implementation, process and impact, and outcome evaluation. 
As further described by Crosby and Noar (2011), this planning model would help explain 
the phenomenon of conducting a process improvement project and identifying measurable 
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variables as it enables to serve as an organizing framework aimed at a health promotion effort. 
The model follows the critical point in the process of planning "backward," meaning that it 
illustrates "working from the end goal to produce objectives and sub-objectives that, if met, will 






















Section III: Methods 
Context 
Clinic leadership must ensure staff has adequate education, resources, and support to 
provide exceptional, competent, and safe care.  As an independent, not-for-profit organization, 
The Joint Commission (2018) certifies healthcare organizations nationwide to maintain specific 
performance standards. Their mission is to improve the public's health by continuously 
evaluating healthcare organizations and inspiring them to provide safe, effective care of the 
highest quality and standards. Dickson (2018) further described that accreditation organizations 
such as the Joint Commission help organizations improve care quality by reducing process 
variation across organizations.  
 Stanford Healthcare, as a Magnet© designated facility, and according to its website, 
Stanford HealthCare (2019) would be responsible for ensuring its nurses had adequate education 
development to provide greater autonomy to deliver the best care. Furthermore, according to 
the American Association of Colleges of Nursing (AACN) (2018), Doctor of Nursing Practice 
(DNP) educated nurses are well prepared to provide evidence-based, quality improvement 
project management initiatives to improve patient outcomes. The research confirms this 
statement as multiple studies show a 10 percent increase in baccalaureate-prepared nurses 
involved in patient care, showed a nine percent decrease in patient deaths.  Advanced nursing 
education has a significant impact on nurses' knowledge and competencies and, therefore, their 
value to the practice setting (AACN, 2018). This data suggest a DNP student is well equipped to 
lead process improvement interventions. This successful change of practice in the Women's 
Cancer Center, Stanford Healthcare local setting has also effectively brought about 
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improvements in patient care education in other oncology clinics through modification and use 
of this educational endeavor.  
 Ultimately, patients were most affected using this process improvement change as they 
benefitted from getting appropriate evidence-based, individualized treatment education and 
toolkit materials to reference.  Key stakeholders related to this process improvement plan were 
the nurses directly impacted by this change in their NC role. Medical providers such as 
physicians or APP's were also affected as traditionally; the APP gave the pre-treatment education 
after the physician went over the patient's plan of care. Supportive personnel such as clinical, 
administrative assistants/ medical assistants are also affected. They helped ensure toolkit 
availability by providing the necessary information that is readily available for the NC to access 
and send the toolkit to the patient's home if needed.  Clinic leadership in the cancer center is also 
critical as it was necessary to gain their approval and provide essential resources to succeed (See 
Appendix B for Agency Letter of Support). 
Interventions 
I intended to improve the process related to NC chemotherapy teaching through 
standardized education and documentation to enable the nurse in the outpatient clinical setting to 
teach the patient population and enhance the patient experience at the first treatment visit. The 
intervention was chosen to positively impact multiple aspects of the workflow and fill 
knowledge gaps associated with chemotherapy teaching.  
To gain information about the mesosystem that makes up Stanford Healthcare's 
outpatient oncology clinics, I moderated a focus group that included 19 NCs from other Stanford 
oncology clinics and infusion areas. The intent was to explore the current state of patient 
education and teaching along with introducing this process improvement plan. Themes identified 
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from the well-attended class included: (a) aligning all groups and roles in standardizing 
chemotherapy regimen teaching (specific chemotherapy regimen teaching and general teaching), 
(b) provide alternative delivery methods (video, binders, 1:1 teaching, group session), (c) How to 
sustain the educational system so that it will not become obsolete (See Appendix N for Focus 
Group Information). 
A PowerPoint presentation was conducted for clinic leadership and stakeholders in the 
breast and gynecology cancer clinics to introduce the intervention, define the quality 
improvement process, explain the importance of pre-treatment education, review the research, 
and discuss recommendations going forward. Qualitative information was collected related to 
nurses' feelings and observations regarding how they felt conducting an educational teaching 
visit with currently available knowledge and materials.  
A toolkit was developed for nurses and patients to utilize when conducting the pre-
treatment chemotherapy session. It was requested from clinic leadership that the author develop a 
nurse-specific checklist to ensure that the nurses had standardized information available to teach 
the patients. The project's projected implementation was January 2020, after developing the 
manuscript and prospectus, which was completed in June 2019.  
The project included 1:1 educational training of the nurses, which lasted approximately 
45 minutes. Some nurses required additional education depending on their level of comfort with 
patient education and prior work experience. Some nurses found it helpful to sit in on an 
educational visit with the author to observe prior to conducting an independent teaching session.  
Gap Analysis 
 
According to Fee-Schroeder et al. (2018), educating patients about their chemotherapy 
treatments and potential side effects is standard practice in most cancer centers. According to the 
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Oncology Nursing Society, it is also a standard of care (Neuss et al., 2017). I conducted a gap 
analysis before initiating this project with an intention to assess and analyze the current state of 
NCs role in teaching chemotherapy naïve patient's pre-treatment education. All aspects of this 
analysis of chemotherapy teaching's current process were completed in collaboration with key 
stakeholders involved in the teaching process.  
Nurse coordinators in these clinics are not fully utilized as supportive clinical 
professionals to help offload the educational burden from the APP to optimize team-based care. 
A current high-level initiative in the women's cancer center clinics encouraging nurse 
coordinators to utilize their education and skills at the highest level to educate its patient 
population has helped transition the nurses to be more engaged and patient-facing. It would 
behoove leadership to support a process improvement plan to help move in that direction.  It is 
anticipated that this process improvement plan with the implementation of a unit-specific toolkit 
will positively impact multiple aspects of the workflow and fill knowledge gaps associated with 
chemotherapy teaching.  
Four objectives were identified from the formal gap analysis: (a) identify information 
clinic nurse coordinators would deem necessary to conduct a pre-treatment educational visit, (b) 
develop specific information to be included in the teaching toolkit, (c) improve communication 
related to the availability of supplemental resources, (d) develop a sustainability plan for current 
and future resource management along with identifying personnel who will take responsibility of 
compiling and maintaining the materials (See Appendix D for Gap Analysis). 
Gantt Chart 
 
A Gantt chart was then developed to illustrate the timeline related to specific tasks and 
complete all milestones on schedule for the project. According to Mindtools (2018), this visual 
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chart can easily be modified and presented to other stakeholders in an easy-to-understand format. 
The project deliverables are listed on the left, with dates on top to estimate timelines. The project 
started with a basic literature review and gap analysis. The aim was to carefully determine the 
problem gaps between current and desired practice and determine if the literature supported an 
evidence-based change to improve patient outcomes by developing a toolkit to enhance nurse 
coordinator education. The "gap" was then be formulated into a PICO question, and the problem 
was further refined to be kept narrow in focus. More extensive and specific literature reviews 
were then conducted utilizing search terms from the PICO question. Stakeholders particular to 
the process improvement plan were identified. A proposal to critical leadership was completed to 
assure buy-in for the strategy and assure the project would be well-aligned with the healthcare 
organization's mission and goals.   
The following steps were then completed and included a plan-specific timeline or work 
breakdown structure, responsibility /communication matrix, SWOT analysis, and budget. This 
information was then submitted in a draft of the proposal to the author’s  DNP chair and the 
second reader to review and was modified as needed. Implementation of the project commenced 
after conducting an anonymous four-question Likert scale NC Pre-treatment education survey of 
NCs in the breast and gynecology oncology units, who were responsible for taking on this 
educational endeavor.  
After developing the toolkit and education to support it, the survey was again conducted 
to compare and determine if there was a positive correlation between the intervention and the 
project outcomes. Lastly, the findings' summary report was presented to all key stakeholders, and 




Work Breakdown Structure 
 
 The work breakdown structure (WBS) is an organized example of the typical flow of a 
"systems development project." According to the University of California Santa Cruz (2019), its 
methodology is broken down into five work stages: Defining, Planning, Launching, Managing, 
and Closing to describe a set of activities or deliverables that help move the project forward. 
Completing a schedule such as this helps organize, define, and tailor the work into more 
manageable increments.  
 In the first phase (define), strategies for identifying the evidence-based question were 
identified by gathering internal evidence and developing a PICO question. A comprehensive, 
systematic literature review was conducted utilizing the PICO components to answer the PICO 
question effectively and efficiently (Melnyk, Gallagher-Ford & Fineout-Overholt, 2017). As 
discussed by Dearholt and Dang (2018), the use of the Johns Hopkins Evidence Appraisal Tools 
helped to critically appraise the most relevant evidence for use in this review. This phase 
concluded by presenting the proposal and executive summary to the critical leadership for 
approval and recommendations going forward.  
 The (plan) or second stage included establishing key stakeholders, developing 
deliverables, and defining milestones to be reached.  The toolkit development needed a small 
team of nurses and APP's who worked in the clinic and had experience conducting pre-
chemotherapy teaching. A project team kickoff meeting took place as I presented the plan to the 
breast and gynecology oncology clinics' stakeholders to help communicate my intention. It was 
recommended that I develop a checklist to ensure consistency in the nurse's teaching.  
A focus group meeting was arranged with the help of the cancer center nurse educator. 
He helped coordinate with nurses from other cancer clinics and infusions areas. This meeting 
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was helpful as I learned how other nurses were conducting pre-treatment teaching and 
communicated my intention to a broad scope of oncology clinic nurses. 
The third stage (launch) included a breakdown of the project workflow to ensure that 
project deliverables and milestones were achieved. The first deliverable was creating a written 
toolkit that included evidence-based information related to managing post-treatment-related 
symptoms, miscellaneous information, and phone numbers. I then developed a nurse knowledge 
and attitude survey to give the nurses before 1:1 education and training. The project was 
implemented in January 2020.  
 The fourth stage (manage) included using PDSA cycles to ensure necessary 
modifications were addressed and change to help the process succeed (IHI,2019).  This phase of 
the project was ultimately slowed due to COVID-19 and difficulty completing the nurses' 
necessary education. After frequent discussion via remote evaluation meetings, the post-survey 
tool was then completed by the nurses.  
The final phase (closeout) consisted of measurement of data and evaluation utilizing 
Excel software to determine the patient improvement project's success. A sustainability plan was 
developed, and further modifications were discussed to help make the toolkit more accessible via 
an electronic version and conduct the clinic visit via remote modalities.  A final wrap of the 
project and resulting data was presented to the stakeholders (See Appendix F for Work 
Breakdown Structure).  
Responsibility Matrix 
 
 The project stakeholders' roles and responsibilities are delineated in the responsibility 
matrix. Specific functions were delegated to include the project unit leader, DNP student, nurse 
coordinators, and APPs who function as nurse practitioners (NPs) or physician assistants (PAs), 
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along with medical oncologists. Other significant players included unit leadership and ancillary 
staff such as clinical, administrative personal, medical assistants, and finally, front desk 
personnel who work to check patients in and out of the clinic. Recognition of the vital members 
is a critical part of the project because it delineates all persons and their responsibilities related to 
the project scope, roles, commitment, and timelines (See Appendix G for Responsibility Plan).  
Communication Matrix 
 
 It was essential to communicate imperative information to persons at the right time. This 
communication plan was developed and managed by the DNP candidate to ensure that the 
project remained within scope, on time, and on budget. The project was initially proposed to 
clinic leadership via an in-person meeting to provide an overview of the specific goals and 
potential impact this process improvement plan would have on improving nurse-led pre-
chemotherapy teaching.  
This project, along with information related to how an evidence-based project can help to 
improve patient care, was discussed during a presentation to stakeholders with an intent to show 
energy and help engage the staff early in the process. Ongoing feedback was also facilitated at 
daily huddles and monthly staff meetings to amend the information in real-time and make 
relevant changes to improve the process. Several edits were made to the toolkit as relative 
information was recommended by staff to make sure necessary information was contained to 
relay to patients prior to starting treatment (See Appendix H for Communication Matrix). 
SWOT Analysis 
 
The development of a  SWOT analysis was completed to analyze the potential strengths, 
weaknesses, opportunities, and possible threats to this intervention. It helped create full 
awareness of the environment and take a proactive approach to enable the project to succeed. 
  
30 
One such strength this author identified is strong leadership support to allow the NC to 
independently teach the pre-treatment educational visit. As a large academic institution, the 
organization encourages nurse leaders to implement evidence-based project improvements. As a 
Magnet-designated facility, the organization's strategic goals align with American Nurses 
Credentialing Center (ANCC) to improve patient outcomes (ANCC, 2018). 
One internal weakness that was identified is the lack of clinical administrative assistant 
(CAA) support personnel to offload the nurse's non-clinical aspects of their workflow. NC 
workflow must be managed to allow them the time to educate the patient adequately. An 
endeavor is currently being implemented in the clinics to help transition these non-nursing tasks 
to CAA's and enable the NC to be more patient-facing.  
Through this analysis, identified opportunities exist to potentially advertise the role of 
NC as an integral asset to the team-based Care that Stanford Healthcare gives its patients. 
Utilizing an NC to assist its patient population in pre-treatment education represents 
a competitive edge. Other extensive healthcare facilities in the Bay area do not currently employ 
a clinical professional in this role. This comprehensive individualized education may also have 
an impact on patient satisfaction scores that will benefit the organization. 
Finally, threats would be the possibility of leadership modifying the team-based role the 
NC currently plays into more of a triage nurse who is less involved in a point-of-care team-based 
patient teaching. Patient pre-treatment education would then transition to a group session not 





This project’s budget was designed using an implementation strategy to introduce new 
education to NC’s and the use of a toolkit with an aim to improve knowledge and comfort levels 
related to how the nurse educates patients starting new treatments. The process improvement 
plan's direct and indirect costs to develop and implement the project were essential information 
when considering this process change. The direct costs comprised personnel time related to 
creating this plan and educating the nurses involved during implementation.  The average 
registered nurse hourly rate, including benefits, according to the manager of these clinics, is 
approximately 94.00/hr. When the time estimated is 30 minutes educational 1:1 session, the cost 
associated with educating 13 nurses would be $611.00. The estimated time for developing the 
toolkit, including pre-and post-surveys and follow-up PDSA, post-implementing of data and its 
related analysis, costing approximately $22,184.00. Time spent communicating the project 
proposal to leadership with an average nurse executive salary hour of $114.00/hour, over two 30-
minute meetings cost roughly $114.00. Indirect costs include printing surveys and reference tools 
along with a folder that makes up the toolkit, which costs approximately $330.00. Total 
estimated costs associated with this 3-month rollout would cost around $ 23,239.00 (See 
Appendix J for Budget).  
Cost/Benefit/Breakeven Analysis 
 
I developed the educational material, and practicum hours were utilized on time spent 
implementing the project. Costs to produce and implement this project totaled approximately 
$23,239.00. Educating the NC was completed during 1:1 session time, and staff were kept 
updated at daily huddles and monthly unit-based committee meetings.  
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Although it is difficult to place a monetary value associated with this improvement 
process, its value on the investment (VOI) is evident. The proposed benefits associated with 
improving nurse coordinator teaching and resulting increase in the patient’s ability to self-
manage post-treatment care are universally positive outcomes. Stanford Healthcare would see 
measurable revenue benefits to the health system by expanding nursing roles and allowing the 
nurse to complete pre-treatment education. By the NC taking over the educational components, 
the APP would be available to see at least one additional patient per day. Based on the ability for 
the APP to be able to take one extra patient a day where it can be billed at $1,200, it would take 
19.37 patients to break even with the costs of the project ($23,239.00/$1,200=19.37). 
It is anticipated that this standardized education and toolkit will also improve nurse 
engagement as a supportive team member in the clinic and potentially reduce nurse turnover in 
the role. The literature supports this assertion as it has been shown by Wan, Li, Zhou, & Shang 
(2018) that links between nurse turnover have been shown to be decreased through the 
development of interventions to support the work environment. These nurse-led clinics also 
provide a professional environment where nurses feel empowered in the multidisciplinary role, 
and it is anticipated that nurse retention could improve due to increased satisfaction in the role as 
an integral part of the patient’s multidisciplinary care team.  
Return on Investment 
 
Dividing the project's anticipated net income by the cost of the investment, you would 
obtain a return on investment (ROI) calculation. For this educational improvement plan, the 
expected net revenue could be as much as $288,000.00 over 12 months divided by its cost of 







Over time it is expected that the project will continue to show improved patient 
outcomes, and costs associated will decrease as upfront costs related to development and 
implementation is complete with periodic review and improvements to be made. With reduced 
average patient contact time spent by the APP educating the patient and offloading this to the 
nurse coordinator will allow for the APP to see an additional patient per clinic day, which at the 
current rate of $1,200 per visit would equate to an additional $288,000.  
Additionally, there is also a potential for the NC to bill for caregiver education under 
Medicare Part B utilizing education codes and documentation supporting the level of work 
performed using a Level 3 or 4 Visit RVU. As noted by (Centers for Medicare & Medicaid 
Services [CMS], 2020), this may generate approximately $25-35 charges per visit, which could 
equate to as much as $6000 over a year’s time (See Appendix K for Expected Revenue). 
Study of the Intervention 
This project required a review of the existing practices in two large academic oncology 
outpatient clinics to assess how patients received education prior to starting new chemotherapy 
treatments. I then developed a toolkit that contained evidence-based materials that were highly 
significant to oncology patient care. The use of the information contained in the final toolkit 
materials was determined to be relevant after review by leadership and clinic colleagues.  
I led a kickoff meeting for the stakeholders with the intent to introduce the QI project.  
Education was shared on how evidence-based projects are conducted following the Institute of 
Healthcare Improvement’s Model of Improvement (IHI, 2021). Gap analysis, project 
management, and Plan-Do-Study-Act (PDSA) cycles were introduced. It was determined after 
this presentation that a nurse coordinator checklist should be developed for use in determining 
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that all necessary information is standardized and utilized in the education component (See 
Appendix 0 for Pre-Treatment Nurse Checklist). 
After implementation of the project, comparisons were made between the nurse’s 
perception of how they felt this education and toolkit would help them independently teach and 
document pre-treatment patient education, along with how this increased knowledge would 
positively impact their workflow as nurse coordinators. Evaluation of the change of practice 
DNP project required the use of a de novo evaluation tool that I developed to help determine 
outcome measures related to the intervention. This tool is without established validity or 
reliability but has shown to be a valuable lesson learned in evaluating this project.  
Outcome Measures 
Data Collection Tools 
 
This project's primary outcome measures included an anonymous [pre-and post-
intervention] Nurse-Led Pre-Treatment Teaching Education Experience Survey, consisting of a 
4-item author-developed Clinic Specific Toolkit Feedback Survey.  The survey was developed 
and delivered to the breast and gynecology nurses at the monthly cancer clinic-based meeting 
and served as the tool development process. It included clinic-specific knowledge, preparedness 
with teaching, documenting, and perception of the teaching visit. Responses ranged on a 4-point 
Likert-type scale from "Strongly Agree" to "Strongly Disagree." Two open-ended questions were 
also included to gain a perception of the challenges of conducting this educational visit, along 
with suggestions to improve satisfaction (See Appendix L for Data Collection Tools). 
Analysis 
The project's participants included (N=13) nurse coordinators working in breast and 
gynecological outpatient cancer clinics at Stanford Healthcare. APPs were not utilized in the data 
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as I wanted to focus solely on how the change in process would affect the nurses in those 
microsystems who will be adapting this change in practice. The pre-intervention survey results 
were used as a baseline for the current perception of a nurse-led pre-treatment teaching 
experience. Quantitative analysis was compared from the pre- and post-surveys with results 
imported into an Excel spreadsheet. Descriptive statistics were used to analyze the data. 
Information obtained from the pre-and post-survey qualitative data was used to inform and 
understand how nurse perception of the training affected their knowledge and comfort levels as a 
nurse coordinator and patient educator. The positive findings show that the educational 
information and basic tenets of this toolkit could be easily modified and adapted in other clinics 
across Stanford’s outpatient macrosystem. It is also anticipated that the information could easily 
be modified over time and adapted as new evidence was received.  
Ethical Considerations 
According to American Nurses Association (ANA) (2017), the nurse's code of ethics and 
human rights statement dictates that nursing must observe a patient's dignity and human rights 
while committing to protect and promote social justice. This quality improvement (QI) process 
improves the nurse coordinator's ability to conduct a pre-treatment educational visit that respects 
the participant's privacy and dignity.  
It is ethically and morally right for patients to expect the best evidence-based information 
to manage anxiety and potential post-depressive symptoms after receiving the recommended 
cancer treatments. The appropriate care does not stop after the patient decides to commence with 
treatment. This is when the most impact can be made to help the patient become educated and 
proactive to decrease an unpleasant experience. Without this information, the patient may 
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experience side effects that contribute to discontinuing treatment before it is recommended and 
have the cancer progress to an uncurable stage. 
As a DNP student attending a school that aligns with the Jesuit faith's values and ethics, I 
feel this project incorporated those practices of cura personalis-care of the whole person and 
brought forth multiple components of caring for the patient (USFCA, 2019). Implementing 
education to nurses with the goal of enabling the patient to utilize self-care interventions with a 
resultant decrease in anxiety fulfills a core tenet of the Jesuit faith. The nurse-patient bond is also 
strengthened as this teaching enables human interaction to be accomplished in a caring manner.                                          
 The process for gaining approval for conducting this change in process evidence-based 
improvement plan involved obtaining authorization from both the University of San Francisco 
and Stanford Healthcare. The university's SONHP DNP committee determined this project 
exempt from the Institutional Review to protect human subjects (IRB) after reviewing the 
student’s statement of determination. The project was deemed a process improvement project. 
Stanford Healthcare, specifically the Women's Cancer Center oncology leadership, also 
supported this project and discussed this and future publications. As a quality improvement 
project, all information and data obtained will remain compliant with the Health Insurance 
Portability and Accountability Act (HIPAA) laws and does not show a conflict of interest (See 








Section IV: Results 
Qualitative Findings  
Information obtained from the Oncology clinic focus group showed common themes 
aligning all groups and roles to standardize chemotherapy regimen teaching throughout the 
oncology clinics and treatment areas. It would help provide alternative delivery methods and 
ensure that the educational system would not become obsolete. The project was introduced to the 
stakeholders via a PowerPoint presentation. Leadership found it necessary that a checklist be 
developed to ensure the nurses were teaching information in a standardized approach.   
The pre-treatment teaching education experience survey contained two open narrative 
questions and information suggests: 
Increased ability to teach this oncology population will lead to reduced post-treatment 
patient messaging and pre-treatment anxiety.  
The NC role would be highlighted as a member of the patient's team.  
This educational visit early in the treatment allows the NC to establish a positive nurse-
patient relationship and become an essential resource.  This visit helps to create a more 
collaborative relationship that benefits both the patient and the nurse.  
Allows the nurse to practice more fully within their scope of practice and reach their 
potential as a healthcare provider.  
Quantitative findings 
Thirteen nurse coordinators from the Breast and Gynecology oncology clinics were 
invited to participate in this educational endeavor. They were given a pre-and post-educational 
survey utilizing a four-point Likert scale ranging from strongly agree to strongly disagree.  
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Four questions evaluated how comfortable the nurses were with the current state of 
nurse-led pre-treatment education. The questions focused on what was expected, specific 
information needed to teach, and how to schedule the patient and document accordingly (see 





I know what is expected of me in conducting an independent   2.90  0.86 
nurse pre-treatment patient educational visit.  
 
I know what specific information should be included in the    2.80  0.89 
nurse pre-treatment patient educational visit. 
 
I understand the process related to how a patient is scheduled for the  2.40  0.65 
nurse pre-treatment patient educational visit.  
 
I understand the process of how to document the information from the  2.50  0.77 
nurse pre-treatment patient educational visit in EPIC. 
 
The mean scores documented were less than 3 for all the questions, suggesting that the 
nurses did not feel they had the knowledge and materials to conduct the patient teaching and 
schedule and document the visit.  Although the nurses have experience working with oncology 
patients in the clinics, the findings suggest that they would need training regarding how to best 
educate patients before starting treatment.  
The post-nurse education/toolkit development scores showed improvements in all areas 
of conducting the pre-treatment educational visit with increased mean values greater than 3 (see 
Table 2 below).  
 
Question  (Range = 0.00 to 4.0) Mean           SD
    




Post-Education Survey  
 
 
I know what is expected of me in conducting an independent                  3.60             0.50 
nurse pre-treatment patient educational visit.  
 
I know what specific information should be included in the                   3.70  0.48 
nurse pre-treatment patient educational visit. 
 
I understand the process related to how a patient is scheduled for the              3.50  0.51 
nurse pre-treatment patient educational visit.  
 
I understand the process of how to document the information from the           3.50  0.51 
nurse pre-treatment patient educational visit in EPIC. 
 
 
I  then completed a t-test to determine if the scores obtained were due to the educational 
endeavor and not by chance. A statistical significance was set at p<0.05. The t-test, p-value 
results indicate that the data received pre-and post-survey were statistically significant for all 
questions (see Table 3 below).  
 
Table 3 



















Mean 2.92 3.62 2.85 3.69 2.38 3.54 2.54 3.46 
 
Std. Deviation 0.86 0.51 0.90 0.48 0.65 0.52 0.78 0.52 











Question   (Range = 0.00 to 4.0)     Mean  SD 




To follow the nurse's perceptions and feelings related to conducting a patient pre-
treatment educational visit over time,  I engaged the support of clinic leadership to have the 
nurses complete a follow-up survey in the following months. It is essential to continue to assess 
if the toolkit information is up to date and supports current evidence (See Appendix M for Pre-





















Section V: Discussion 
Summary 
Data to support the project shows that project aims were met. See discussion below. 
Aim one: Achieve more than 20 percent increase in RN knowledge base related to 
imperative information necessary to educate the patient before the first treatment. Comparing 
data from the pre-and post-survey questions indicated a rise of 24 % related to what information 
was essential to discuss with the patient at the pre-treatment educational visit.  
Aim two: Achieve more than > 20 percent increase in RN knowledge related to the 
nurse's role in conducting an independent pre-treatment educational visit. Data obtained from 
pre-and post-survey questions showed a rise of 32 % of how the nurses felt they were 
knowledgeable about their role in conducting this educational visit.  
Aim three: Achieve more than 20 percent increase in RN knowledge related to 
scheduling the pre-treatment educational visit. This question had the most significant increase 
in nurse knowledge associated with preparing the educational visit as the data showed a rise of 
46 %. 
Aim four: Achieve more than 20 percent increase in RN knowledge related to the pre-
treatment educational visit documentation. This question and the data amassed showed a rise of 
40 % of nurses' understanding of documenting the pre-treatment clinic visit. 
Overall, the data demonstrate an increase in nurse knowledge of 35%. This positive 
statistic shows this DNP student met the goals of increasing nurse knowledge by 20% to take on 
this educational endeavor. This project's success in the Stanford Healthcare breast and 
gynecological oncology clinics helps potentially bring about positive change related to the role 
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of NC. This change in process could also be adapted for use in other oncology clinics throughout 
the system.  
It is anticipated that this improved pre-treatment education will enhance the overall 
patient experience and strengthen the nurse-patient bond as this evidence-based communication 
shows compassion and empathy related to helping the patient manage treatment-related side 
effects. Increased communication between the treating team and the patient will help encourage 
the patient to reach out to the clinic if they are unable to self-manage treatment-related side 
effects. The information included in the toolkit encourages the patient to notify the clinic or 
after-hours nurse line if they felt they needed additional recommendations. Utilizing established 
outpatient resources may help to decrease hospital ED visits as many concerns could be 
addressed by the treating team or triage nurse before needing admission to the hospital. This may 
help decrease overall healthcare costs upstream.  It might be of value to conduct a retrospective 
review of the data to see how this relationship may affect patient outcomes and patient 
satisfaction scores.  
Interpretation 
 As a cancer patient moves beyond diagnosis, there becomes a need for the provider to 
introduce the plan of care along with education related to evidence-based treatments to give the 
patient the best curative chance. As the delivery of these treatments continues to move toward 
outpatient care, herein lies the challenge of sharing important information with the patient to 
improve health outcomes.  
The oncology nurse's ability to educate its patient population as part of the 
interprofessional clinical team should not be taken for granted. Not all nurses are well prepared 
to take on this endeavor.  Adapting and embracing the role of patient educator as a fundamental 
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nursing responsibility, with the proper preparation, will give the nurse the ability to shape patient 
outcomes along with their primary care environment (Marshall & Sigma Theta Tau, 2016). The 
challenge then becomes how to communicate this information before the patient commences 
with treatment effectively. 
Patients are willing to take steps to effectively self-manage the side effects of cancer 
treatments if they are empowered with evidence-based information and tools. As a result of 
increased awareness of how to lessen unpleasant symptoms, we also anticipate increased 
compliance and improved health outcomes.  
Limitations 
There were limitations encountered regarding the implementation of the project. This 
author initially anticipated to teach the nurses and pilot the intervention over three months, but 
due to  Covid-19 implications, the author extended this aspect of implementation to 
approximately five months. As noted by the CDC and other governmental agencies, it was 
recommended to conduct work via remote modalities and stay at home to avoid illness spread 
and exposure (CDC, 2020).  Stanford Healthcare mandated staff to take time off to help with the 
institutional budget and transition to remote work. This made it challenging to communicate 
effectively with the nurses and encourage them to conduct pre-treatment educational visits.  
Some promising outcomes of remote work included the necessity of conducting some 
patient care sessions via online modalities, such as Zoom or Video Visits. These online visits 
allowed us to modify our workflow to accommodate patients that may live far or have concerns 
with in-person clinical or educational visits and is a process that we anticipate continuing post-




This project aimed to develop, implement, and evaluate the effectiveness of using unit-
specific education and tools to improve the NC's ability to conduct a pre-treatment educational 
visit for newly diagnosed cancer patients in outpatient cancer clinics. The project was supported 
and developed using the best available evidence-based information, current literature, and 
established project management methods. This standardized toolkit enables the NC to schedule 
and efficiently teach a patient necessary information and, in turn, adequately document this in the 
patient's electronic health record (EHR). This change of practice positively affects NC workflow 
as the NC now has the necessary education and tools to work at or above their education and 
training level. This patient-centered approach also helps the oncology team as the APP's are no 
longer asked to conduct this teaching and can increase patient volumes.   
The nurse-led pre-treatment training increases patient's knowledge before undertaking a 
stressful and potentially unpleasant chapter in their lives. The information gained allows the 
patient to self-manage side effects proactively and gives them a sense of control when life seems 
uncontrollable.  
Long-term effects of the use of this educational information and toolkit are that it is 
easily modified to be utilized in a variety of outpatient oncology clinics throughout the larger 
system, and new staff may be educated in its use. I have participated in several meetings with 
clinical educators aligned with outpatient and inpatient care at Stanford Healthcare to discuss this 
QI project and its contents and how it may be utilized in other areas at Stanford.  This is an 
ongoing effort that I intend to be aligned with to offer my support as needed. It is also anticipated 
that clinic leadership will ensure ongoing use and sustainability of this process as positive results 
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have shown improved quality of care, increased nurse coordinator satisfaction and engagement, 


























Section VI: Funding 
Funding for the cost of materials, flyers, printing, and toolkit information came from 
Stanford Oncology Women's Cancer SQIMM funds. This DNP candidate's work consisted of 
voluntary use of time to develop the toolkit content, implement the process, and analyze the 
findings. All the time spent on the project was approved and encouraged by the student's clinic 
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Section VIII: Appendices 
 
Appendix A: IRB and Statement of Determination 
 
 
DNP Statement of Non-Research Determination Form:  Laura Oka                                                                                            
Title of Project:  Improving Nurse-Led Oncology Pre-Treatment Education  
Brief Description of Project: The oncology nurse coordinator's role in a large academic 
outpatient oncology clinic is continually being modified to assist the patient care team 
better to improve patient education. This education consists of pre-treatment care planning 
and conducting a clinic visit to educate the chemotherapy-naive patient before 
treatment. Historically, this education has been given by the Advanced Practice 
Professional (APP). As nurse coordinators are now taking on a more prominent role in 
patient education, a gap has been identified about how effective the nurse is in conducting 
this educational visit and having access to standardized references to utilize during the 
clinic visit. 
A pilot had been proposed and is supported by leadership to evaluate the effectiveness of 
instituting a clinic-specific reference toolkit to improve the Registered Nurse (RN) comfort 
level of conducting the visit.  
A) Aim Statement: By January 2021, develop, implement and evaluate a pre-treatment 
toolkit to be utilized for newly diagnosed cancer patients at Stanford Healthcare outpatient 
oncology clinics. 
B) Description of Intervention: This Doctor of Nursing (DNP) change of practice project 
will have several phases.  
The first phase will involve the DNP student working with key stakeholders to develop the 
clinic-specific evidence-based reference tools to be utilized during the pilot. As the 
facilitator in this project, the DNP student will build a compelling business case based on 
peer-reviewed literature presented to leadership to gain approval for the pilot project.  
The second phase will involve working with the clinic RN's to engage and elicit feedback 
via an anonymous survey to improve the toolkit's effectiveness and before the pilot's 




The third phase will be the pilot's actual launch and gaining feedback related to the toolkit's 
flow. A post-survey will be conducted to assess the RN's comfort and confidence in 
independently conducting this educational pre-treatment clinic visit with the toolkit's 
assistance.  
Identified stakeholders at a clinic-based council meeting will anonymously provide 
feedback by completing a brief 5-point Likert-type scale to assist in and give feedback on 
the proposed reference tool content, organization, appropriateness, and ease of use help in 
tool development.  
 
All RN's who utilized the new process and its content will then be asked to complete a 
post-pilot 5-point Likert-type scale survey related to their comfort level and confidence in 
conducting the pre-treatment visit, utilizing the toolkit, and rate this perceived experience. 
Results will be measured by comparing pre-and post-intervention mean scores.  
 
C) How will this intervention change practice? By implementing an evidence-based 
reference toolkit, it is anticipated that improvements will be made to increase the nurse 
coordinator's effectiveness to work at the highest level of their education. This will then 
allow the APP to focus on seeing patients independently in-clinic appointments.  
D) Outcome measurements:  
 
1. RN knowledge base related to imperative information necessary to educate the 
patient before the first treatment will increase by 20 %. 
2. RN's ability to utilize specific information included in the nurse pre-treatment 
toolkit will increase by 20 %. 
3. RN knowledge base related to how the pre-treatment educational visit will be 
documented will increase by 20 %. 
4. RN knowledge base related to how a patient is scheduled for a nurse pre-treatment 
patient educational visit will increase by 20 %.  
 
To qualify as an Evidence-based Change in Practice Project, rather than a Research Project, the 
criteria outlined in federal guidelines will be used:  
(http://answers.hhs.gov/ohrp/categories/1569)  
 This project meets the guidelines for an Evidence-based Change in Practice Project as 
outlined in the Project Checklist (attached). The student may proceed with implementation. 
 This project involves research with human subjects and must be submitted for IRB approval 










Appendix C: Evidence Evaluation Table 
Citation Evidence Type Sample 
Size & 
Setting  
Study Findings Limitations Evidence & 













education is more 
valuable than a broad 
group class 
Metrics were not 
kept/Small 













patient needs along with 
effective education 
ensures a more positive 
patient experience 















Facilitated discussion by 
an oncology nurse 
increases patient 
knowledge r/t 
chemotherapy side effect 
management and self-care 
strategies to manage 
Two limitations 























preparation is suboptimal, 
and not much research has 
studied how this affects 
patient distress regarding 
treatment-related 
concerns. A nurse-led 
prechemotherapy 
educational intervention 
shows promise to improve 




size. The study 
was undertaken at 
a single specialist 
cancer center and 





















improves the patient's 
understanding of their 
upcoming treatments 
using standardized 
checklists to provide a 
teaching framework. 
Calendars are also helpful 
and should be 





when the session 
was conducted 
from 2 weeks 
before the first 
treatment or the 






















Nurse navigator support 
for patients with early 
cancer significantly 
improved the patient 
experience and reduced 
care problems but did not 
affect the quality of life 
Limitations 
included the 
atypicality of the 
setting, lack of 






















The inclusion of an 
oncology nurse navigator 
results in a shorter time 
lapse between diagnosis 















inclusion of the 
multidisciplinary 
tumor board may 
have influenced 





































potential adverse effects, 
and antiemetic medication 
regimen showed 
significant increases after 
undergoing a teaching 
session by an oncology 
nurse before commencing 






related to the 
patient's cancer 
staging was not 
utilized as some 
stages are not 
curable and 
palliative in 









Current Status Deficiency Action Plan 
Identifying information clinic, NC deems 
most valuable to know to give the pre-
treatment teaching session. 
 
 
No feedback initiative has ever 
been completed to identify 
knowledge gaps among NC to 
identify education gaps related 
to independently conducting 
the pre-treatment educational 
visit.   
Knowledge/comfort levels related 
to NC's conducting a pre-treatment 
educational visit vary by 
individuals as some nurses have 
some experience with this. 
Communicate with 
relevant stakeholders to 
discuss and determine 
what information would 
be deemed valuable and 
included in the teaching 
toolkit. 
Develop clinic-specific reference sheets to 
capture and identify pertinent information. 
No initiative has ever been 
undertaken to develop specific, 
universal teaching materials 
for use in the clinic to teach 
patients who are starting 
chemotherapy treatments. 
  No specific reference sheets 
currently exist for utilization by the 
NC to conduct a teaching session. 
Some educational information 
exists related to APP teaching but is 
not consistent. 
Collaborate with clinic 
stakeholders to develop 
evidence-based clinic-
specific reference sheets 
to be utilized in the 
teaching toolkit. 
Improve communication of availability of 
clinic toolkit resources. Assign 
responsibility of supportive personal to 
make sure the toolkit is compiled and 
readily available.  
The majority of NC and 
support personnel are not 
aware of supplemental clinic 
recourses available to conduct 
a pre-teaching session. 
Without specific, universal teaching 
materials, the NC is not 
consistently teaching the new 
chemotherapy treatment patients. 
This may lead to patients not 
receiving effective pre-treatment 
education.  
Promote the use of the 
toolkit supplemental 
information availability 
and location of such 
information in daily clinic 
huddles. 
Develop and implement a 
sustainability/responsibility plan for future 
resource management of toolkit recourses. 
 
No sustainability/ 
responsibility plan exists for 
resource management 
currently. 
Without the necessary toolkit 
information available, the NC will 
need to compile and print data. 
Knowledge needs to be up to date 
and modified as required.  
NC and clinic leadership 
review and revise clinic-
specific resources sheets 
annually to change and 
update as needed. 
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Breakdown of project 
workflow 
Administer pre-
intervention survey to 
nurses 
Introduce and educate 
nurses on toolkit 
through 1:1 and group 
meetings as needed 
Sit in on real time 
chemotherapy teaching 
session with nurses. 
Obtain and give feed-
back 
PDSA’s completed and 
modify toolkit or nurse 
education as necessary 
Administer post-
implementation survey to 
nurses  
Outcomes evaluation 
and present data to 
stakeholders 
Sustainability plan: 
Assign admin to ensure 
toolkits are available 












DNP Student Project manager/facilitator Facilitate development, implementation, 
rollout, progression, data analysis, and 
closeout 
Unit leadership Promoter Grant initial approval for the plan. 
Provide feedback for process flow issues 
and guidance throughout 
Clinic-based Nurse Coordinators (NC’s) Facilitator and Collaborators Tool development, rollout, and project 
progression at the unit level 
Unit Clinical Administrative/Medical 
Assistants (CAA’s) 
 
Facilitator and Distributor Tool disbursement 
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Appendix H: Communication Matrix 
 
 








Nurse Manager and lead 
APP 
8/2019 In-person meeting DNP student 




Clinic nurses, APP's 
MD's, administrators, 
and medical assistants  
        9/2019-12/2019 In-person presentation 
at monthly CCP 
meeting 
DNP student 






7/2019 In-person during daily 
AM huddles for two 





Clinic nurses, APP's 12/2019 Email to target audience 
and survey to be placed 
in each nurse's mailbox 
DNP student 
Project pilot start, 
progression, up 
dates & close-out 
 
All key stakeholders 1/2020-6/2020 In-person monthly CCP 
meeting, a weekly 





Clinic nurses, APP's 7/2020 Email to target audience 
and survey to be placed 
in each nurse's mailbox 
DNP student 
Communication of 
project results & final 
presentation 
All key stakeholders 12/2021 CCP monthly meeting DNP student 










 Strong executive leadership and management level support 
 Large academic facility utilizing evidence-based protocols and 
interventions 
 Nurse advocacy is inherent to the role of the nurse coordinator 
 Multiple studies in the literature related to process improvement 




 Limited research-related (cohort studies, RCTs, evidence summaries) 
articles as the subject matter did not yield literature of this type  
 Lack of administrative support personnel to offload non-clinical 
workflow 
 Poor rapport with some providers between the nurse coordinator and 
MD/APP 
 Decreased engagement due to high acuity/stress within the clinic 




 Promote the role of nurse coordinator as an integral asset to the 
team-based care that Stanford Healthcare gives its patients.  
 
 This comprehensive individualized education may also have an 







 Decreasing the role of NC in the oncology clinics at Stanford Healthcare 
due to monetary restraints 
 
  Possibility of leadership modifying the team-based role the NC 
currently plays into more of a triage nurse who is less involved in point 
of care patient teaching 
  
65 











*Cost per provider for outpatient visit for evaluation and treatment of a new patient with an RVU of 5. 
**Estimated increase in annual revenue of seeing additional patients (Days per year (240 days/year)). 
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Appendix L: Data Collection Tools 
 
Nurse-led Pre-Intervention Education Experience Survey 
1. I know what is expected of me in conducting an independent nurse pre-treatment patient 
educational visit.  
    
⃞  Strongly agree        ⃞  Agree         ⃞  Disagree       ⃞  Strongly Disagree  
 
2. I know what specific information should be included in the nurse pre-treatment patient 
educational visit. 
 
⃞  Strongly agree        ⃞  Agree         ⃞  Disagree       ⃞  Strongly Disagree  
 
3. I understand the process related to how a patient is scheduled for the nurse pre-treatment 
patient educational visit.  
 
⃞  Strongly agree        ⃞  Agree         ⃞  Disagree       ⃞  Strongly Disagree  
 
4. I understand the process of how to document the information from the nurse pre-
treatment patient educational visit in EPIC. 
 




How do you feel the education and use of the nurse-led pre-treatment patient education will 







How do you feel your contribution as a team member in the nurse coordinator role is 
highlighted or not highlighted by having the nurse coordinator conduct the nurse-led pre-






Nurse-led Post-Intervention Education Experience Survey 
 
 
1. I know what is expected of me in conducting an independent nurse pre-treatment patient 
educational visit.  
    
⃞  Strongly agree        ⃞  Agree         ⃞  Disagree       ⃞  Strongly Disagree  
 
2. I know what specific information should be included in the nurse pre-treatment patient 
educational visit. 
 
⃞  Strongly agree        ⃞  Agree         ⃞  Disagree       ⃞  Strongly Disagree  
 
3. I understand the process related to how a patient is scheduled for the nurse pre-treatment 
patient educational visit.  
 
⃞  Strongly agree        ⃞  Agree         ⃞  Disagree       ⃞  Strongly Disagree  
 
4. I understand the process of how to document the information from the nurse pre-
treatment patient educational visit in EPIC. 
 




How do you feel the education and use of the nurse-led pre-treatment patient education will 
likely change your practice? 
 
 
How do you feel your contribution as a team member in the nurse coordinator role is 
highlighted or not highlighted by having the nurse coordinator conduct the nurse-led pre-



























I know what is expected of




I know what specific
information should be
included in the nurse pre-
treatment patient
educational visit.
I understand the process
related to how a patient is
scheduled for the nurse pre-
treatment patient
educational visit.
I understand the process of
how to document the
information from the nurse
pre-treatment patient
educational visit in EPIC.







I know what is expected of




I know what specific
information should be
included in the nurse pre-
treatment patient
educational visit.
I understand the process
related to how a patient is
scheduled for the nurse pre-
treatment patient
educational visit.
I understand the process of
how to document the
information from the nurse
pre-treatment patient
educational visit in EPIC.
















Appendix O: Pre-Treatment Nurse Checklist 
 
 Nurse Coordinator Pre-Treatment Educational Visit Checklist 
 Intro: 
• Introduce yourself and your role, including working together as a team (MD, APP, 
Fellow, Resident, CAA, and MA). 
 
 
 Need for Systemic treatment: 
• Cancer treatments may consist of surgery to remove the tumor tissue, systemic 
therapies such as IV Chemotherapy treatments, Radiation, and oral anti-estrogen 
inhibitors. These treatments are recommended to give you the best chance of killing 
any cancer cells locally or those potentially circulating in your body 
 
 How does Chemotherapy work? 
 
• Typically, cells live, grow and die predictably. Cancer occurs when specific cells in 
the body keep dividing and forming more cells without the ability to stop this process. 
Chemotherapy protocols involve destroying cancer cells by keeping the cells from 
further multiplying. Unfortunately, in the process of undergoing chemotherapy 
protocols, healthy cells can also be affected, especially those that naturally should 
divide quickly. 
 
• Chemotherapy drugs that kill cancer cells only when they are dividing are called cell-
cycle specific. Chemotherapy drugs that kill cancer cells when they are at rest are 
called cell-cycle non-specific. The scheduling of chemotherapy is set based on the 
type of cells, the rate at which they divide, and the time at which a given drug is 
likely to be effective. Therefore, chemotherapy is typically given in cycles. 
 
 Why you may experience common side effects: 
 
• Chemotherapy is most effective at killing cells that are rapidly dividing. 
Unfortunately, chemotherapy does not know the difference between cancer cells and 
normal cells. The "normal" cells will grow back and be healthy, but, in the meantime, 
side effects occur. The "normal" cells most affected by chemotherapy are blood cells,  
cells in the mouth, stomach, bowel, and hair follicles, resulting in low blood counts, 
mouth sores, nausea, diarrhea, and/or hair loss. Different drugs may affect other parts 
of the body. Fortunately, we have very effective medications to help manage these 
unpleasant side effects.  
 




Your Doctor has chosen specific chemotherapy drugs based on  
• Research: specific protocols based on cancer type, stage, and other specifics. 
• Response rates: established through years of research and is how a type or stage 
of cancer will respond to a particular drug. 
• The health of the patient; due to the toxicities of chemotherapy, risk vs. benefit 
must be taken into consideration when deciding treatments.   
 
• (Go over specific common agents' side effects related to the patient’s 
chemotherapy. Print out the chemotherapy sheets from Chemocare.com to 
include in the toolkit) 
 
 Adjuvant vs Neoadjuvant treatment: 
 
• Adjuvant treatments consist of having surgery followed by chemotherapy and 
then radiation if indicated. 
• Neo-adjuvant consists of having chemotherapy up-front to help shrink the tumor's 
size and assess response to treatment. Surgery is then completed, followed by 
radiation if indicated.  
 
 Three main agents:  
-ACT=Adriamycin (Doxorubicin) & Cytoxan (Cyclophosphamide), which will be given 
Q3 weeks X 4 cycles 
Followed by: 
-Taxol (Paclitaxel) given weekly X 12 cycles or DD Q 3 weeks X 4 cycles 
 
-TC= Taxotere (Docetaxel) and Cytoxan (Cyclophosphamide), which will be given every 
three weeks X 4-6 cycles 
 
-TCHP= Taxotere (Docetaxel), Carboplatin (Paraplatin), Herceptin (Trastuzumab), and 
Perjeta (Pertuzumab) given every three weeks X 4-6 cycles with Herceptin and (possibly 
Perjeta) to complete one year of treatment. 
 
 Nadar Affects Blood Cell and Platelet Counts: 
• When chemotherapy is given, it not only affects the rapidly dividing cancer cell, 
but it also involves some of the normal cells of the body.  These effects mainly 
occur on normal cells that divide quickly, such as the hair, the lining of the mouth, 
the cells lining the intestinal tract, and the blood cells (white and red blood cells 
and platelets).  
 
• The nadir time is usually about 7-10 days after treatment, although this may vary 
depending on the drugs given. During the nadir time, the concern is that the 
body's first line of defense against infection, white blood cells (WBC), is low, 
leaving a person more susceptible to disease.  The next dose of chemotherapy is 





• Neulasta or (Pegfilgrastim) is a colony-stimulating factor, meaning it is given 24 
hours after receiving chemotherapy to help stimulate the growth of “health” WBC 
in the bone marrow. We now have a device called Onpro, an on-body injector 
placed on your skin, and self-inject a preprogrammed amount of medication while 
you are at home. Your infusion nurse will show you a video and explain how it 
works at your first treatment. 
 
• This medication sometimes causes body ache and bone pain. The pain may be 
alleviated by taking Claritin daily in the morning of days 2-6. You may also use 
Tylenol/Motrin as needed for pain.  
 
 Medi Port, Echo, labs, home meds: 
 
• An implanted port is sometimes recommended before starting specific 
chemotherapy treatments due to potential injection site reactions and treatments' 
longevity.  
 
• An Echocardiogram (ECHO) is an ultrasound test of your heart to evaluate how 
well the left ventricle functions. It is usually recommended for Her2 directed 
treatments such as Herceptin and Perjeta, baseline and every three months 
throughout treatment. It is also recommended to have a baseline ECHO before 
starting Doxorubicin.  
 
• We will have you obtain labs before each treatment to assess how your body 
reacts to the chemotherapy. Walk walk-in labs do not require an appointment, and 
our infusion schedulers will schedule port labs.  
 
• At-home medications will be sent to your pharmacy of choice, and we will go 
over the recommended schedule of how to take the best to prevent symptoms of 
nausea/vomiting after each treatment. Please make sure you pick them up before 
starting treatment. 
 
 What happens in the infusion center? 
 
• Your team of providers at the infusion center are highly trained oncology nurses 
and are available to answer many of your questions. They are also trained to help 
manage  chemotherapy reactions/allergies if they occur.  
 
• It is advised to wear comfortable clothes to the treatment. Eat a light breakfast and 
bring some snacks/lunch with you as you may be there for many hours. You may 
also bring your computer, iPad, earphones, or a good book with you. The staff 





• The sequence of treatments will be IV fluids and pre-meds followed by 
chemotherapy and then more hydration.  
 
 




• Body ache 
• Muscle ache 
• Lack of appetite** 
• Nausea 
• Mouth Sores** 
• Constipation/Diarrhea 
• Decreased blood counts (anemia/depressed immune system/risk of bleeding) 
• Hair loss 
• Allergic symptoms (itching/hives/swelling are the most common) ** 
• Numbness/tingling in the hands and feet (Neuropathy)**  




The best way to treat nausea/vomiting is to prevent it! These are the recommended medications to 







• Decadron if receiving Taxotere: Some treatment medications such as Docetaxel 
require you to take three days of a steroid called Decadron at each cycle's start. The 
use of this steroid is to decrease the side effect of a treatment reaction and have the 
added benefit of helping reduce nausea related side effects 
 
• *If you are taking the at-home medications as recommended and are still having 
N/V or are unable to keep foods or fluids down, please notify us as you may need 
to come in to get hydration or IV anti-nausea medications in the ITA. 
 
    Constipation: 
 
Some anti-nausea medication, as well as chemotherapy, may cause constipation. You may find it 







• Smooth Move Tea 
Other more natural options that may work for you: 
• Drink 2-3 litters of fluid/day 
• Try to get moderate exercise 20-30 minutes/day 
• Limit alcohol to 1 glass/day 
• Try ground fresh flax seeds over your cereal.  
• Fresh celery sticks 




You may find that you alternate between constipation and diarrhea during chemotherapy. If you 
have diarrhea: 
 
• BRAT diet: bananas/rice/apple sauce/ toast 
• Increase fluid intake 
• OTC Imodium as directed 
 
 Mouth Care: 
 
If you have mild soreness or mouth redness: 
• Brush with a soft toothbrush 4X/day 
• Apply a lip moisturizer 
• Avoid consuming scalding hot liquids 
• Arrange to have a checkup with your dentist before starting treatments. 
 
-1 Tablespoon of baking soda and 1 Tablespoon of salt in 2 pints of water. Swish and gargle 4 
four times/day 
-Avoid over the counter mouth rinses like Listerine or Scope as they have alcohol in them  
-Biotin Mouthwash three times/day (to help prevent mouth sores) 
-Stomatitis cocktail (prescription numbing mouthwash if you develop open mouth sores)
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Low White Blood Cell Count or symptoms of infection/sickness 
 
If you develop a temperature >100.4, F or 38 C, you must notify us promptly. Monday thru 
Friday, during regular hours, you may call us at 650-498-6004. The call center will send us an 
urgent page to call you back and get more information.  After hours, weekends, evenings, or 
holidays you need to call the after-hours line any time at 650-723-6661 to discuss with a triage 
RN or MD.  
 
Fevers can be a sign of infection, and if your WBC is low, it is difficult for your body to fight 
infection. You may be asked to come in to get lab work done and may be asked to start taking 
antibiotics.  
 
 Miscellaneous Info: 
 
• Drink at least 2-3 liters of water/day (8-10 glasses or 2-3 quarts) every day, unless 
directed otherwise by your doctor. Fluid examples may be water, juice, sports 
drinks, broth, soup, popsicles, and jello 
• Avoid eating raw fish 
• Handwashing is the number one defense to fight off infection.  
 
 When should I call my healthcare team? 
 
• A fever of 100.5 F or greater 
 
Supportive Care program 
 
• #650-725-9456  
• www.cancer.net American Society of Clinical Oncology (ASC). This is an evidence-
based website containing evidence-based information. 
 


















Appendix P: Pre-Planning Tool 
 
   Pre-Planning Tool 
 
 












SCANS     PRE-PLANNING 
 
 
CT CAP _________   Beacon Plan entered ________     
      Authorization OK’d    ________ 
 
Bone Scan _______   Port__________________ 
 
PET ________     ECHO_________________ 
 
Outside Path review ________  Labs__________________ 
 
Outside Scan Review ________  Home Meds____________ 
 
       Oncotype _________   Pharmacy______________ 
  
      Chemo teach___________ 
 
      1st Appointment Scheduled _____________ 
                               











Appendix Q: Chemo Fact Sheet 
 
 
Stanford Women’s Cancer Center 
Breast Oncology Chemotherapy Fact Sheet 
 
A Guide to Cancer Infusion Therapy 
 
Your oncology team will review the schedule for your 
chemotherapy, depending on your treatment plan. 
Schedules may change for many reasons. We ask that you be as flexible as possible with 
treatment days and times. Please notify the scheduler in advance of your preference in location 
and time (we will do our best with your request, but unfortunately, we can’t guarantee this will 
happen). Unexpected events about your treatment and/or the treatments of other patients can 
often cause delays. You may have less stress if you do not make other commitments on the day of 
your infusion appointment.  
 
Your chemotherapy will be given through an IV (intravenously). The treatment is provided in the 
ITA (Infusion Treatment Area), located at one of our 3 locations.  
 
Stanford Cancer Center Infusion Treatment Locations 
875 Blake Wilbur Drive           450 Broadway Street                2589 Samaritan Drive 
              2nd Floor                                 Pavilion B35, 3rd Floor              4th Floor 
              Palo Alto, CA 94304               Redwood City, CA 94063          San Jose, CA 95124 
              Phone: 650-725-1860            Phone: 650-724-6140               Phone: 408-426-4900 
 
Tests before treatment  
 
You may need some tests before starting your treatment. These help the doctors make sure 
you’re well enough to have your treatment. They will usually include blood tests and maybe 
urine or heart tests. Sometimes, you may also need to have x-rays or scans before treatment 
starts. Before each treatment cycle, it is normal to have a blood test and see the doctor or nurse. 
This may be on the day of your treatment or a day or two before it. They will check your blood 
results and ask you how you have felt since your last treatment. 
 
Along with the chemotherapy, you will be receiving fluids to hydrate you and medications to 
help prevent nausea and sometimes allergy symptoms (ex. itching).  If your IV access is difficult 
or painful for you, ask us about a central venous port (a more permanent IV access placed under 





Common Side Effects of Chemotherapy  
** Discuss with your care team if you have these symptoms. 
• Fatigue** 
• Body ache 
• Muscle ache 
• Lack of appetite** 
• Nausea 
• Mouth sores 
• Constipation/Diarrhea 
• Decreased blood counts (anemia/depressed immune system/risk of bleeding) 
• Hair loss 
• Allergic symptoms (itching/hives/swelling are the most common) ** 
• Numbness/tingling in the hands and feet ** 
• Chest pain/Shortness of breath/lower extremity swelling** 
Not all side effects are experienced by every patient.  Every chemotherapy drug has a different 
set of side effects.  Depending on your treatment plan, we will let you know which side effects to 
be concerned about most. 
 
Below will review some techniques to manage the common symptoms 
 
Nausea/Vomiting:  
This symptom is usually well controlled with the proper medications.  We rarely have patients 
who have vomiting after treatment.  More commonly, patients will describe mild nausea or lack 
of appetite for a few days after treatment.  The best way to treat nausea is to prevent it!  We will 
give you medications during the chemotherapy and ask you to take some medicines at home to 
help prevent the onset of nausea.  Below are the medications you should take with your 
treatment. 
Start these medications as advised. Take them on a schedule as below during the hours you are 
awake.  Sometimes these medications can need prior authorization from your insurance before 
you can get it- your pharmacy will let you know if you need this, and our team will help you get 
it authorized.  Not all chemotherapy will require a nausea regimen. We will tell you what we 
recommend you take. 
 
⎕ Zofran (ondansetron) 8mg - Start the morning after your chemo infusion. Take one tablet 
every 8 hours for 2 to 3 days after treatment. 
 
⎕ Ativan (lorazepam) 1mg - Start the evening of your chemo infusion. Take one tablet at 
bedtime for 2 – 3 days starting the infusion day to help you sleep and prevent nausea/vomiting.  
 
⎕ Compazine (prochlorperazine) - 10mg Take one tablet every 6-8 hours as needed for nausea if 
Zofran is not effective. 
 
 
If your chemotherapy is particularly more nauseating or we find that the above medications are 




⎕ Emend (aprepitant) 150mg IV. We can add this to your premedication through the IV. 
⎕ Aloxi IV 0.25mg/5ml – infused before chemotherapy. 
⎕ Decadron 4mg- take one tablet twice daily for two days after chemotherapy. 
We can make other changes to help control nausea if needed, such as additional hydration in the 




Chemotherapy, as well as the medications we use for pain or nausea, can cause constipation.  We 
recommend that your start taking a mild laxative the day of chemotherapy to help prevent this.  
Please use one of the following: 
 
 
Please mark the medications that are appropriate for your patient: 
 
⎕ Colace 100mg (docusate sodium) Take 1-2 tablets twice daily (stool softener) 
⎕ Senokot Take 1-2 tablets twice daily for constipation 
⎕ MiraLAX 17g Mix with water or juice and drink daily (this is a suitable medication for daily 
     maintenance, it does not work well once you are constipated) 
⎕ Smooth move tea (gentle) for those who are more sensitive to laxatives. Available at Whole 
Foods or other natural grocers.  
 
Other more natural options that may or may work for you: 
• Drink 2-3 liters of fluid per day (especially if you take a fiber supplement or have a high-
fiber diet) 
• Try to get moderate exercise 20-30 minutes per day 
• Limit alcohol to 1 glass per night 
• Try ground fresh flax seeds over your cereal.  
• Try fresh celery sticks 





Some patients will alternate between constipation and diarrhea during the chemotherapy.  If you 
have diarrhea: 
 
⎕ BRAT diet: bananas/rice/apple sauce/toast 
⎕ Drink plenty of fluids. Avoid sugary or processed foods that can exacerbate diarrhea. 
⎕ Imodium Over the counter, take as directed 
Mouth Care 
If you have mild soreness or mouth redness: 
• Brush with a soft toothbrush 4x/day and floss daily 
• Apply a lip moisturizer 
• Avoid consuming scalding liquids 




⎕ 1 Tablespoon of baking soda and one tablespoon of salt in two pints of water. Swish and 
gargle 4 
      times a day. 
⎕ Avoid over the counter mouth rinses like Listerine or Scope 
⎕ Biotin Mouthwash three times daily (to help prevent mouth sores) 
⎕ Stomatitis cocktail (prescription numbing mouthwash if you develop open mouth sores) 
 
Allergic/Hypersensitivity Reactions 
These reactions are more common with certain chemotherapy medications than others.   They 
usually occur during the infusion.  Symptoms include itching, flushing, hives, shortness of 
breath, chest tightness, and low blood pressure.  The symptoms typically resolve with Benadryl 
and sometimes from steroid medication.  Rarely are the reactions more severe. 
 
If you have a mild reaction, we may ask you to take allergy medication before chemotherapy and 
possibly a low-dose steroid called Decadron.  
 
 
Low White Blood Cell Count 
Your white blood cells are your infection-fighting cells (immune system).  You may be at risk 
for this, depending on the type of treatment you are receiving.  The more chemotherapy you 
receive, the more at risk your bone marrow is for low white blood cell counts. 
White cells typically go down to their lowest approximately 7-10 days after chemotherapy and 
then start to recover. This is called the Nadir. 
 
If you ever have a fever at home >100.5 F or 38 C, you need to call our office during regular 
business hours at 650 498-6004 or after hours: Please call 650-723-6661 
 
Fevers can be a sign of infection, and if your white count is low, it is difficult for your body to 
fight infection. We will likely ask you to come in to have your blood counts checked, and you 
may need antibiotics. 
 
If your blood counts are getting too low before each treatment, we may use a medication to help 
stimulate your bone marrow to make more white blood cells. 
 
Neulasta (pegfilgrastim) 6mg subcutaneous ONE time the day after chemotherapy. 
This is a LONG-ACTING form of Neupogen.  
It is given once after chemotherapy. 
We can give it to you in the ITA 24 hours after chemotherapy.  You may also receive this 
medication in the form of a patch that self-injects 24 hours after chemotherapy called Onpro.  
Your infusion nurse (chemotherapy nurse) will again go over how to manage the patch. 
You should not receive chemotherapy again for at least 14 days after this injection. 
 
This medication can cause body ache and bone pain (back/chest/long bones). The pain can be 
alleviated by taking Claritin daily in the morning of days 2-6 each cycle.  You may also use 




Muscle and Joint aches 
Muscle aches can be caused by chemotherapy. They typically start the day after treatment and 
can last for 2-3 days.  Paclitaxel is one of the chemotherapy drugs we give that can cause this.  
You can take anti-inflammatory drugs such as Motrin/Ibuprofen or Tylenol to help with the pain.  
Warm packs/ warm baths/and massages are also good options.   Not everyone will experience 
these symptoms, and for some, they may be very mild. 
 
Miscellaneous info: 
• Drink at least 2-3 liters (8-10 glasses or 2-3 quarts) every day unless directed otherwise 
by your doctor. Examples of fluids are water, juice, sports drinks, broth, popsicles, and 
jello. 
• Avoid eating any raw fish, raw eggs, or raw meat. It is okay to eat fruits and vegetables. 
Make sure to wash them well.  
• Hand washing is the number one defense to fight infection. Please be sure to wash your 
hands frequently. 
 
When should I call my healthcare team? 
 
• A fever of 100.5° Fahrenheit, or greater. 
• Bleeding or unusual bruising. 
• Burning and/or pain when urinating. 
• Constipation (no bowel movement in 2-3 days). 
• Diarrhea (loose, watery stools) - four or more watery stools in 24 hours. 
• Nausea, vomiting, or if you cannot keep down any liquids. 
• Your current medications do not control pain. 
• Redness, pain, sores, or a white coating in your mouth. 
• Shaking and chills. 
• Unusual cough, sore throat, lung congestion, or shortness of breath. 
 
You may also get additional instructions about when to call your healthcare team. 
 
We are here to help support you and allow you to complete the treatment safely and as 
comfortably as possible.  Please stay in close touch with us (my health online is an easy way to 
ask quick questions or let us know how you are doing) to help manage symptoms and do our best 
to maintain your quality of life through this journey.  
 
Depending on our treatment plan and the type of work you do, some patients will continue to 
work on a part-time basis through treatment.  If you choose to take time off, we can have our 
administrative coordinator contact you to help with forms and letters. 
 
Important Phone Numbers 
If you have a question or concern: Please call 650-498-6004 
 
• Leave a message with the phone operator, and you will receive a call back from our nurse 
coordinator the same day 
  
84 
• If your question is determined to be urgent, you will be transferred to a triage nurse who 
will contact the appropriate provider (MD/NP) to answer your concern 
 
If you have a non-urgent question for your doctor or nurse practitioner: 
• You may communicate with them over “My Health.” 
• “My Health” is a secure email system within Stanford that we can use to share important 
information from your health record with you 
• Ask our staff how you can sign up for “My Health.” 
• Please be aware we do not monitor this portal on evenings, weekends, or holidays 
If you are experiencing a medical problem after hours: Please call 650-723-6661 
• If this is a life-threatening condition, call 911 
• Do not send a my-health message during after-hours as we do not monitor this portal. 
• Ask to speak with the breast oncology on-call staff  
• Someone is always available to assist you 
• Appointments: Please call 650-498-6004 
• For an appointment in the ITA (infusion treatment area) 
• After your visit, if you need to schedule a radiology test: Please call 650-723-6855 
• If you need to obtain copies of medical records: Please call 650-723-5721 
• If you need to schedule an ECHO test for your heart: Please call 650-723-7406 
Cancer Supportive Care Program 
Our supportive cancer care program offers: 
• Educational classes and workshops such as lymphedema, chemotherapy, and radiation 
classes 
• 1:1 exercise consultation with cancer care specialist offering various yoga, palates, 
Taiichi, dance, and exercise classes 
• Mindfulness meditation 
• Support groups 
• Healing touch, wig band, skincare, and scarf tying class 
Please call 650-725-9456 to get more information or go to the supportive care website: 
https://standordhealthcare.org/for-patients-visitors/cancer-supportive-care-program-html 
 
www.Cancer.net for Doctor-Approved Patient Information from American Society of 
Clinical Oncology (ASCO) 






Appendix R: At Home Medication Management 
Patient Name: ____________________________ M RN__________________ Treatment__________________________________________  
4/3/2020 
Recommended at home symptom management medications 
  
*You may continue to take as needed after Day 3 post treatment. 






Day 2 after Chemo Day 3 after Chemo Miscellaneous 
Information 
Zofran (Ondansetron) 
8 mg by mouth every 8 
hours for Nausea 
* 













Side effects are:  
Headaches and constipation 
Compazine 
(Prochlorperazine) 
10mg by mouth every 6-
8 hours for Nausea 
* 
 
  As needed 
every 6-8 
hours 
As needed every 6-8 
hours 
As needed every 6-8 
hours 
Side effects are sleepiness 
and twitching or anxious 
feeling 
Ativan (Lorazepam) 
1 mg by mouth at 








by mouth to alleviate 
swelling, prevent 

























  Helps to prevent allergic 
reactions and may help to 
increase appetite. May 
cause insomnia  
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Appendix S: Bay Area Wigs 
 
 
Bay Area Wig & Hairpiece Source 





Face to Face hair salon (custom hair pieces and wigs) 
157 W Portal Ave #1 
San Francisco, CA 94127 
415.566.2806 
 
Hair replacement by Janet (custom hair pieces and wigs) 
1371 Laurel St. 
San Carlos, CA 84070 
659.592.3691 
 
Hansen Fontana Inc. (Hair wigs/cranial prosthesis. Fully custom made or predesign wigs) 
536 Bryant Street 
San Francisco, CA 94107 
414.495.8888 or 800.495.8881 
 
The Wig Source at John Muir women’s health center (only in twice a month. Used and new wigs. Appt only) 
1656 N. Calif Blvd.  
Walnut Creek, CA 94596 
925.947.5328 
 
Marzel’s Inc. (breast prosthesis, surgical bras, lymphedema, synthetic wig pieces) 
5980 Stoneridge Dr. Suite 119 
Pleasanton, CA 94588 
925.227.1402 
 
1220 Oakland Blvd. 
Walnut Creek, CA 94596 
925.939.2450 
 
Paris Fashion Wigs (storefront wigs, no custom wigs) 
568 S Murphy Ave 
Sunnyvale, CA 94086 
408.737.2504 
 
House of Wigs (hair for every women) 
238 Plaza Central  
Los Altos, CA 94022 
650-559-00073 
 
American Cancer Society (some free and donated wigs) 
1720 S Amphlett Blvd. 
San Mateo, CA  
650.578.9902 
 
1715 S Bascom 
Campbell, CA  
408.879.1032 
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